2056030-06-7

Basic information

• Product Name: N-[4-chloro-3-(trifluoromethyl)phenyl]-N′-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea p-toluenesulfonate
• CAS NO: 2056030-06-7
• Molecular Weight: 637.03
• Mol File: 2056030-06-7.mol
• Article Data: 33

Chemical Properties

• CAS DataBase Reference: N-[4-chloro-3-(trifluoromethyl)phenyl]-N′-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea p-toluenesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-chloro-3-(trifluoromethyl)phenyl]-N′-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea p-toluenesulfonate(2056030-06-7)
• EPA Substance Registry System: N-[4-chloro-3-(trifluoromethyl)phenyl]-N′-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea p-toluenesulfonate(2056030-06-7)

Safety Data

• Hazardous Substances Data: 2056030-06-7(Hazardous Substances Data)

Usage

Uses

Sorafenib Hemitosylate is a drug used for the treatment of human hepatocellular carcinoma (HCC), but its effect on HCC is limited in clinical use.

Upstream product

• 1199618-55-7 sorafenib ethane sulphonate 
• 104-15-4 toluene-4-sulfonic acid 
• 327-78-6 4-chloro-3-(trifluoromethyl)phenyl isocyanate 
• 284462-37-9 4-(4-aminophenoxy)-N-methylpyridine-2-carboxamide 
• 284461-73-0 sorafenib 
• 220000-87-3 4-chloro-N-methylpicolinamide 
• 320-51-4 4-chloro-3-trifluoromethyl-aniline 
• 50528-73-9 4-benzyloxy-phenyl isocyanate 
• 6373-46-2 p-benzyloxyaniline 
• 1145-76-2 benzyl 4-nitrophenyl ether 
• 100-02-7 4-nitro-phenol 
• 1152131-62-8 1-(4-benzyloxy-phenyl)-3-(4-chloro-3-trifluoromethyl-phenyl)-urea 
• 6192-52-5 p-toluenesulfonic acid monohydrate 
• 123-30-8 4-amino-phenol 

Relevant articles and documents

Impurity Free and Scalable Process of Sorafenib Tosyalte: Hepatocellular Carcinoma

An efficient, impurities free and scalable process of hepatocellular carcinoma and renal cell carcinoma of sorafenib tosylate with good quality and higher yield.

Sorafenib hemicamsylate and processes for preparation thereof

The present invention relates to: novel sorafenib hemi camsylate salt for treating cancer (chemical formula III); a novel crystalline form thereof; and a method for manufacturing the same. More specifically, the present invention relates to: hemi camsylate salt having high stability, solubility, and purity; a crystalline form thereof; and a method for manufacturing the same. The problem to be solved by the present invention is to provide novel sorafenib salt which is easy to make various preparations, and the method for manufacturing novel salt.COPYRIGHT KIPO 2020

Method for preparing sorafenib tosylate salt targeted anti-tumor drug

The invention discloses a method for preparing a sorafenib tosylate salt targeted anti-tumor drug. The method is characterized in that a synthesis route is as followings (please see the specificationsfor the synthesis route), wherein carbonate (M2CO3) in the synthesis route is sodium carbonate, potassium carbonate or cesium carbonate, and a solvent in the synthesis route is MDF or DMA. The carbonate is adopted to replace potassium tert-butoxide, reaction operation is greatly simplified, and the cost is lowered; and through repeated testing and condition screening, the problem of excessively long reaction time is solved finally through heating reflux.